Lungs News and Research

RSS

No safe level of exposure to secondhand smoke

The following is a statement by Cheryl G. Healton, DrPH, President and CEO of Legacy on the U.S. Surgeon General's Report:

13 Dec 2010

Pomegranate juice exhibits potential to prevent metastasis of prostate cancer cells to the bone

Researchers at the University of California, Riverside have identified components in pomegranate juice that both inhibit the movement of cancer cells and weaken their attraction to a chemical signal that promotes the metastasis of prostate cancer to the bone. The research could lead to new therapies for preventing cancer metastasis.

13 Dec 2010

Cancer researchers identify six gene markers in early stage NSCLC

Cancer researchers have identified six gene markers present in early stage non-small cell lung cancer (NSCLC) that show promise in helping oncologists better identify which tumors will relapse after curative surgery, according to a study presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

New initiative launched to fight cystic fibrosis

The University of British Columbia, in partnership with the Canadian Cystic Fibrosis Foundation (CCFF) and the Centre for Drug Research and Development (CDRD), today launches the Cystic Fibrosis Technology Initiative (CFTI) to advance Canadian technologies that will help combat cystic fibrosis (CF).

13 Dec 2010

Research programs embody the promise of anti-aging medicine.

Sometimes the value of research lies as much in exposing false remedies as in discovering true breakthroughs. Scientists at the country's first school of gerontology and in laboratories around the University of Southern California do both, mindful of their responsibility to a society focused on healthful aging.

13 Dec 2010

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim Pharmaceuticals, Inc. announced that new data from a subgroup analysis of the phase IIb/III LUX-Lung 1 trial show that afatinib (BIBW 2992) reached a four-fold extension (4.4 months vs. 1.0 month for placebo) in progression-free survival (PFS) in advanced non-small cell lung cancer (NSCLC) patients most likely to have an epidermal growth factor receptor (EGFR) mutation. The updated LUX-Lung 1 data will be presented at the Chicago Multidisciplinary Symposium in Thoracic Oncology.

13 Dec 2010

Study shows stereotactic radiation therapy as effective as surgery in elderly patients with early-stage lung cancer

A new study shows that a new type of targeted radiation therapy called stereotactic radiation therapy is just as good as surgery for patients aged 75 and older with early-stage lung cancer, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

13 Dec 2010

High CTC level found to be early marker of poor outcome in metastatic breast cancer

A high level of circulating tumor cells (CTCs) - cells that have detached from a tumor and are circulating in the body through the blood - are an independent prognostic marker in metastatic breast cancer as first-line therapy.

13 Dec 2010

New MyHospitals website stumbles against criticism

The government’s brand new MyHospitals website faced criticism on its first day, with allegations that old data is being displayed that is far from the current truth. The site is comparing emergency department and elective surgery care in 769 public and 153 private hospitals across the country.

12 Dec 2010

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Ipilimumab used in combination with paclitaxel/carboplatin for stage IIIb/IV non-small cell lung cancer showed superior results in progression free survival when compared to paclitaxel/carboplatin alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and the University of Chicago.

10 Dec 2010

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Tomophase Corporation, developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS™) and other devices, announced today that it has received FDA 510(k) clearance to market OCTIS.

10 Dec 2010

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

A new study shows that a combination of epigenetic therapy and molecular targeted therapy has promising results at combating advanced lung cancer according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology. This symposium is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (ISLAC) and The University of Chicago.

10 Dec 2010

Harvard Bioscience files two major patents in regenerative medicine

Harvard Bioscience, Inc., a global developer, manufacturer and marketer of a broad range of specialized products used to advance life science research and regenerative medicine, has filed two major patents in the field of regenerative medicine, the first covering 61 claims for its stem cell therapy injectors and the second for 338 claims for bioreactors for organ growth.

From Harvard Bioscience 10 Dec 2010

Simple molecular sensor color test to determine safe fluoride levels

Used in the proper amounts, it can make teeth stronger and aid in the treatment of osteoporosis. When excessive amounts are consumed, however, it can be a killer - a carcinogen that causes bone, lung and bladder cancers. The "it" is fluoride, a common additive in most American communities' drinking water and an ingredient in the vast majority of commercially produced adult toothpastes.

10 Dec 2010

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, announces clinical results from ENCORE 401, a double-blind, placebo-controlled phase 2 trial, in patients with advanced non-small cell lung cancer (NSCLC). The results show that there was a survival advantage in the subset of patients with elevated E-cadherin (a molecular marker of epithelial tumors) receiving entinostat in combination with erlotinib (Tarceva®).

10 Dec 2010

People exposed to North Dakota road materials face increase risk of developing mesothelioma

New data shows that people exposed to the mineral erionite found in the gravel of road materials in North Dakota may be at significantly increased risk of developing mesothelioma, a type of lung cancer most often associated with asbestos exposure, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology.

10 Dec 2010

COPD becomes third leading cause of death in the U.S.

The Centers for Disease Control (CDC) and Prevention's National Center for Health Statistics (NCHS) released a report today, "Deaths: Preliminary Data for 2008," confirming that Chronic Obstructive Pulmonary Disease (COPD) became the third leading cause of death in the U.S. for 2008.

10 Dec 2010

Exposure to tobacco smoke causes immediate damage leading to serious illness or death

Exposure to tobacco smoke - even occasional smoking or secondhand smoke - causes immediate damage to your body that can lead to serious illness or death, according to a report released today by U.S. Surgeon General Regina M. Benjamin. The comprehensive scientific report - Benjamin's first Surgeon General's report and the 30th tobacco-related Surgeon General's report issued since 1964 - describes specific pathways by which tobacco smoke damages the human body and leads to disease and death.

10 Dec 2010

Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency

Talecris Biotherapeutics, Inc. announced today the initiation of a clinical trial evaluating the safety and the pharmacokinetic profile of two doses of PROLASTIN®-C (Alpha(1)-Proteinase Inhibitor [Human]) (A1PI), a therapy indicated for chronic augmentation and maintenance in adults with emphysema due to alpha(1)-antitrypsin (AAT) deficiency. AAT deficiency is a rare, genetic disorder in which low levels of the alpha(1) protein circulating in the lungs can increase an individual's risk of developing emphysema.

10 Dec 2010

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

10 Dec 2010

Lungs News and Research

No safe level of exposure to secondhand smoke

Pomegranate juice exhibits potential to prevent metastasis of prostate cancer cells to the bone

Cancer researchers identify six gene markers in early stage NSCLC

New initiative launched to fight cystic fibrosis

Research programs embody the promise of anti-aging medicine.

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Study shows stereotactic radiation therapy as effective as surgery in elderly patients with early-stage lung cancer

High CTC level found to be early marker of poor outcome in metastatic breast cancer

New MyHospitals website stumbles against criticism

Ipilimumab in combination with paclitaxel/carboplatin for stage IIIb/IV NSCLC shows superior results

Tomophase receives FDA 510(k) clearance to market Optical Coherence Tomography Imaging System

Epigenetic-molecular targeted therapy combination holds promise against advanced lung cancer

Harvard Bioscience files two major patents in regenerative medicine

Simple molecular sensor color test to determine safe fluoride levels

Entinostat plus erlotinib improves survival in NSCLC patients with elevated E-cadherin

People exposed to North Dakota road materials face increase risk of developing mesothelioma

COPD becomes third leading cause of death in the U.S.

Exposure to tobacco smoke causes immediate damage leading to serious illness or death

Talecris initiates clinical trial to evaluate 2 doses of PROLASTIN-C for emphysema due to AAT deficiency

Stereotactic radiation therapy as effective as surgery for patients with early-stage lung cancer

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News